A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression

BACKGROUND: Depressive disorders are considered to be one of the leading causes of morbidity and mortality accounting for 4.3% of total disability-adjusted life years. Selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors have greater efficacy and lesser side effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Bathla, Manish, Anjum, Shazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074431/
https://www.ncbi.nlm.nih.gov/pubmed/32201441
http://dx.doi.org/10.4103/ijp.IJP_618_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074431/
https://www.ncbi.nlm.nih.gov/pubmed/32201441
http://dx.doi.org/10.4103/ijp.IJP_618_18

Ejemplares similares